Telness Tech partners with Lebara to Launch New Mobile Operator in Nigeria
20.11.2024 15:43:00 EET | Business Wire | Press release
Telness Tech, a leading telecom technology provider, is partnering with VAS2Nets and Lebara to launch a new Mobile Virtual Network Operator (MVNO) in Nigeria. The initiative will introduce a telecom service aimed at the rapidly growing telecommunications market in Nigeria. The operator will be powered by Telness Tech industry leading software and customer experience, while bringing Lebara, an internationally recognized telecom brand – to an entirely new region and expansive market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241118892327/en/
from the left; Jonas Cedenwing (Founder CTO, Telness Tech), Teniola Stuffman (Group Executive Director Business Development VAS2Nets), Martina Klingvall (Founder, CEO Telness Tech) (Photo: Business Wire)
In this ambitious partnership, several international telecom companies have joined forces to make this venture possible.
Lebara is one of world’s most recognized MVNOs with direct operations in five European markets, and brand licenses in further five countries - now including Nigeria. Telness Tech’s fully automated platform will streamline, automate the new operator, enabling industry leading customer experience. Processcom will also play a key role, providing the mobile core infrastructure necessary for the network’s functionality. With Vas2Nets as the leading partner, coordinating all international companies in this joint endeavor.
Martina Klingvall, CEO and Founder of Telness Tech, expressed excitement about the collaboration: "This international partnership allows us to bring our cutting-edge telecom technology to Nigeria and is an important step in Telness Tech’s rapid international expansion, following our recent entry into the U.S. market. To enable such a massively recognized brand as Lebara to enter yet another market, combined with our advanced technology and VAS2Nets local expertise - will bring a world class service that to Nigeria’s digital population."
The multi-million-dollar agreement spans several years and includes the launch of both prepaid and postpaid mobile services, with future for PBX solutions. Telness Tech will provide the critical OSS and BSS platforms, ensuring smooth customer management and operations. VAS2Nets, the lead partner, will spearhead the launch of this new operator, which aims to be one of the first new mobile operators to go live in Nigeria.
Teniola Stuffman, Group Executive Director of Business Development at Vas2Nets, highlighted the importance of the collaboration:
"This project enables us to offer Nigerians a high-quality, affordable mobile service through the combined expertise of VAS2Nets, Telness Tech, and Lebara and Processcom. Enabling us to deliver one of the first new mobile operators in Nigeria in years, and with the best technology and offerings on top of that. Rest assured, we’re very proud to lead this joint endeavor”
Daniel Upson, Director of Partnerships at Lebara, comments: “I’m extremely excited about combining all of these capabilities together, between our brand, Telness Tech’s technology and VAS2Nets local expertise, I believe we will deliver a truly world class experience for mobile consumers in Nigeria.”
About Telness Tech
Telness Tech is international software company behind the highest-rated digital mobile operator in Europe, Telness, (4.9/5 on Trustpilot) and was originally founded in 2016. Telness Tech enables cloud-based mobile operators (MVNOs) and other telecommunications companies to launch fully digital user-centric solutions that maximize customer satisfaction and minimize costs through full automation
About VAS2Nets:
Vas2Nets is a technology solutions provider in Nigeria, focused on delivering high-quality telecom services that cater to the growing digital economy in West Africa. Providing a one-stop shop, to individual and business customers, to meet all their mobile digital services and digital banking requirements. VAS2Nets leverages its cutting-edge technology, expertise, licenses and relationships to deliver innovative mobile and digital solutions.
About Lebara:
Lebara is a leading international telecommunications brand known for providing affordable, reliable mobile services to diverse communities around the world. Since its inception, Lebara has grown to serve millions of customers across multiple countries, including the UK, Denmark, the Netherlands, France, and Germany. Through strategic brand licensing partnerships, Lebara is expanding into emerging markets, aiming to bridge the digital divide and connect people globally.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241118892327/en/
Contacts
Sebastian Stecki
Vice President, Marketing & Communications
+46 79 104 10 40
sebastian@telnesstech.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom